Figure 2.

The prevalence of abnormal liver stiffness measurement (LSM) values among patients with rheumatoid arthritis receiving methotrexate with a cumulative dose of leflunomide over 19,170 mg. Abnormal LSM values were more frequently identified in patients with cumulative doses of leflunomide ≥ 19,170 mg than in those with cumulative doses of leflunomide < 19,170 mg (69.2% (9/13 patients) vs. 15.0% (6/40 patients), P < 0.001).